



US 20210290537A1

(19) **United States**(12) **Patent Application Publication**
McGHEE et al.(10) **Pub. No.: US 2021/0290537 A1**(43) **Pub. Date: Sep. 23, 2021**(54) **LIPOSOMAL ELINAFIDE FORMULATIONS
AND USES THEREOF****Publication Classification**(71) Applicant: **MALLINCKRODT LLC**, Hazelwood,
MO (US)(72) Inventors: **William McGHEE**, Fenton, MO (US);
Rick FITCH, O'Fallon, MO (US)(51) **Int. Cl.***A61K 9/127* (2006.01)*A61K 9/00* (2006.01)*A61K 31/473* (2006.01)*A61P 35/00* (2006.01)(52) **U.S. Cl.**CPC *A61K 9/1271* (2013.01); *A61P 35/00*
(2018.01); *A61K 31/473* (2013.01); *A61K*
9/0019 (2013.01)(21) Appl. No.: **16/467,458**(22) PCT Filed: **Dec. 8, 2017**(86) PCT No.: **PCT/US2017/065229**


§ 371 (c)(1),

(2) Date: **Jun. 6, 2019**

(57)

ABSTRACT

The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and elinafide, wherein less than 20% of the elinafide is released in vitro from the liposome within 40 hours. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and elinafide, wherein the administration of the liposomal composition has a reduced occurrence of side effects, such as for example, muscle myopathy in the patient.

Related U.S. Application Data(60) Provisional application No. 62/431,524, filed on Dec.
8, 2016.**A****% Release of Elinafide in FBS at 37C****B****% Release of Elinafide in FBS at 37C**